With significant upside potential, Liquidia Corporation (NASDAQ:LQDA) secures a spot on our list of the best small-cap biotech stocks to buy according to analysts. Raymond James Remains Bullish on Liquidia (LQDA), Cites YUTREPIA’s 75% Growth in U.S. Prostacyclin Revenue On November 4, 2025, Raymond James raised its price target on Liquidia Corporation (NASDAQ:LQDA) from $41 to $47, while reiterating a “Strong Buy” rating. The investment firm’s bullish stance reflects YUTREPIA’s 75% growth in U.S. prostac ...

In this piece, we discuss the 10 Best Small-Cap Biotech Stocks to Buy According to Analysts.Small-cap biotech stocks are marking their latest resurgence, attracting renewed investor attention. This resurgence, which follows a prolonged period of underperformance, is driven by a broader market rotation and improving technical indicators. Healthcare, including biopharma, is emerging as a constructive sector as investors pull money out of tech, Craig Johnson, Piper Sandler’s Chief Market Technician, highlighte ...

Liquidia Corp (NasdaqCM:LQDA) 2025 Conference November 10, 2025 04:15 PM ET Company ParticipantsJason Adair - Chief Business OfficerMichael Kaseta - COO and CFOModeratorThis Healthcare Conference, and the next company presenting here today is Liquidia. Really, really excited to have Michael Kaseta, who is the Chief Operating Officer and Chief Financial Officer, and Jason Adair, who is the Chief Business Officer. Thanks, guys, for joining.Michael KasetaAppreciate it.ModeratorExciting times with the story. Ye ...

Shares of Liquidia Corporation (LQDA) have gained 9.7% over the past four weeks to close the last trading session at $26.42, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $42.89 indicates a potential upside of 62.3%.The average comprises nine short-term price targets ranging from a low of $6.00 to a high of $67.00, with a standard deviation of $16.92. While the lowest estimate ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .Today, I am putting Liquidia Corporation ( LQDA ) in the spotlight for the first time since my last review on this small cap commercial stage concern back in January of this year. The conclusion ofBret Jensen has over 13 years as a mark ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .Today, I am putting Liquidia Corporation ( LQDA ) in the spotlight for the first time since my last review on this small cap commercial stage concern back in January of this year. The conclusion ofBret Jensen has over 13 years as a mark ...

We recently published 10 Firms Stealing Market Spotlight Amid Bloodbath. Liquidia Corp. (NASDAQ:LQDA) is one of the best-performing stocks on Tuesday. Liquidia soared by 10.67 percent on Tuesday to close at $27.91 apiece, just 92 cents shy of its highest 52-week price, as investor sentiment was bolstered by strong demand for its pulmonary hypertension treatment. In an updated report, Liquidia Corp. (NASDAQ:LQDA) said that total revenues in the third quarter of the year soared by 1,134 percent to $54 mill ...

Liquidia Corporation, trading on NASDAQ under the symbol LQDA, is a biopharmaceutical company focused on developing therapies for rare cardiopulmonary diseases. The company uses its proprietary PRINT Technology to create innovative treatments, particularly for pulmonary hypertension. Liquidia's competitors include other biopharmaceutical firms that specialize in similar therapeutic areas.On November 3, 2025, Jefferies upgraded Liquidia's stock to a "Buy" rating, with the stock priced at $25.22. This upgrade ...

Financial giants have made a conspicuous bullish move on Liquidia. Our analysis of options history for Liquidia (NASDAQ:LQDA) revealed 29 unusual trades.Delving into the details, we found 55% of traders were bullish, while 31% showed bearish tendencies. Out of all the trades we spotted, 8 were puts, with a value of $1,103,505, and 21 were calls, valued at $1,159,055.Expected Price MovementsBased on the trading activity, it appears that the significant investors are aiming for a price territory stretching fr ...

Core Points - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1] Summary by Categories Technical Requirements - Users are advised to enable Javascript and cookies in their browsers to ensure proper functionality [1] - The presence of ad-blockers can lead to blocked access, necessitating their temporary disablement [1]